Bicycle Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
07 Fevereiro 2024 - 9:00AM
Business Wire
Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company
pioneering a new and differentiated class of therapeutics based on
its proprietary bicyclic peptide (Bicycle®) technology, today
announced that management will participate in a fireside chat at
the Oppenheimer 34th Annual Healthcare Life Sciences Conference on
February 14, 2024, at 10 a.m. ET.
A live webcast of the fireside chat will be accessible from the
Investor section of the company’s website,
www.bicycletherapeutics.com. A replay of the webcast will be
archived and available following the event.
About Bicycle Therapeutics Bicycle Therapeutics is a
clinical-stage biopharmaceutical company developing a novel class
of medicines, referred to as Bicycle® molecules, for diseases that
are underserved by existing therapeutics. Bicycle molecules are
fully synthetic short peptides constrained with small molecule
scaffolds to form two loops that stabilize their structural
geometry. This constraint facilitates target binding with high
affinity and selectivity, making Bicycle molecules attractive
candidates for drug development. The company is evaluating BT8009,
a Bicycle Toxin Conjugate (BTC®) targeting Nectin-4, a
well-validated tumor antigen; BT5528, a BTC targeting EphA2; and
BT7480, a Bicycle TICA® targeting Nectin-4 and agonizing CD137, in
company-sponsored Phase 1/2 trials. In addition, BT1718, a BTC that
targets MT1-MMP, is being investigated in a Phase 1/2a clinical
trial sponsored by the Cancer Research UK Centre for Drug
Development. Bicycle Therapeutics is headquartered in Cambridge,
UK, with many key functions and members of its leadership team
located in Cambridge, Mass. For more information, visit
bicycletherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240207654804/en/
Investors: Stephanie Yao SVP, Investor Relations and
Corporate Communications ir@bicycletx.com 857-523-8544
Media: Argot Partners Deborah Elson media@bicycletx.com
212-600-1902
Bicycle Therapeutics (NASDAQ:BCYC)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Bicycle Therapeutics (NASDAQ:BCYC)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025
